Medical device industry leaders react to U.S. Supreme Court ruling
Everyone — almost everyone – had something to say about the U.S. Supreme Court ruling that upheld most of the Affordable Care Act. We talked to people from all around the industry and here is what they had to say.
For more reactions, check out these posts:
“AdvaMed supported goals of healthcare reform consistent with our long-held principles. We have consistently opposed the $29 billion medical device tax because of its damaging effects on economic competitiveness, jobs and the research and development needed to find tomorrow’s treatments and cures. The House has already voted to repeal the device tax, and we are heartened by the number of senators who have said they oppose the tax. We will continue to work with policymakers on both sides of the aisle to achieve this goal.” – Stephen J. Ubl, AdvaMed president and CEO
“We began planning for implementation of the measures in the Affordable Care Act long ago. We have been engaged in payment and delivery system reform changes that started before passage of the ACA in the private sector and that will continue. We remain committed to executing on our key strategies, which will allow us to succeed in any environment.” – Amy Von Walter, spokeswoman at Medtronic
“I’m a bit surprised. My instinct would be that the individual mandate would be struck down, but in the opinion written by Chief Justice [John] Roberts, it has been repositioned as a tax in the legal sense and therefore would not be struck down. The biggest question mark and concern remains the 2.3 percent excise tax on domestic medical device manufacturers’ revenues. The question beyond that question is just how far reaching the device tax may be.” – Dane Stout, executive director of Connected Health Practice, Anson Group LLC